Beyond Crohn’s disease, the company sees big potential in treating organ transplant rejection, lung inflammation and graft-versus-host disease, which, when combined, are worth tens of billions of dollars worldwide.
According to global research cited by NeuroScientific, the Crohn’s disease therapeutics market is forecast to reach US$13.8 billion (A$21b) by 2026, while related segments such as lung disorders and graft-versus-host disease could grow to US$33b (A$50b) and US$5.3b (A$8b) respectively.
More patients are set to receive StemSmart treatment as fresh doses come online. The first batches will be released from Perth’s East Metropolitan Health Service once they clear final quality checks, while Isopogen’s partner at the Queensland Institute of Medical Research stands ready to ramp up production once its certification is locked in.
NeuroScientific’s broader pipeline of products also includes a protein-based compound called “EmtinB”, which is designed to latch onto specific cell receptors. Once the compound connects, it sparks a chain of signals inside the cell that promote healing, nerve growth and reduce inflammation.
Modelled on a natural human protein called Metallothionein-IIA, EmtinB mimics the body’s own defence system. The company says the early tests have been promising, showing it is safe, precise and well tolerated even at high doses.
With four patients now on treatment, the first round of clinical results is expected in January 2026. If the outcomes are favourable, they could propel NeuroScientific into its next major growth phase – moving from early access treatments to formalised trials aimed at bringing a new class of stem-cell therapy closer to market.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
